These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21377448)

  • 21. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
    Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
    Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
    J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.
    Amir E; Ocaña A; Seruga B; Freedman O; Clemons M
    Cancer Treat Rev; 2010 Aug; 36(5):410-5. PubMed ID: 20100635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
    Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
    Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
    D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
    Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RON confers lapatinib resistance in HER2-positive breast cancer cells.
    Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
    Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 28. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
    Giuliano M; Hu H; Wang YC; Fu X; Nardone A; Herrera S; Mao S; Contreras A; Gutierrez C; Wang T; Hilsenbeck SG; De Angelis C; Wang NJ; Heiser LM; Gray JW; Lopez-Tarruella S; Pavlick AC; Trivedi MV; Chamness GC; Chang JC; Osborne CK; Rimawi MF; Schiff R
    Clin Cancer Res; 2015 Sep; 21(17):3995-4003. PubMed ID: 26015514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
    Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lapatinib for breast cancer: a review of the current literature.
    MacFarlane RJ; Gelmon KA
    Expert Opin Drug Saf; 2011 Jan; 10(1):109-21. PubMed ID: 21091041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
    Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
    Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
    Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
    Zhao H; Faltermeier CM; Mendelsohn L; Porter PL; Clurman BE; Roberts JM
    Oncotarget; 2014 Dec; 5(24):12704-14. PubMed ID: 25587029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving treatment of HER2-positive cancers: opportunities and challenges.
    Stern HM
    Sci Transl Med; 2012 Mar; 4(127):127rv2. PubMed ID: 22461643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
    Peck J; Wei L; Zalupski M; O'Neil B; Villalona Calero M; Bekaii-Saab T
    Oncology; 2012; 82(3):175-9. PubMed ID: 22433475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
    Rani S; Corcoran C; Shiels L; Germano S; Breslin S; Madden S; McDermott MS; Browne BC; O'Donovan N; Crown J; Gogarty M; Byrne AT; O'Driscoll L
    Cancer Res; 2014 Jul; 74(14):3821-33. PubMed ID: 24876102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
    Ma C; Niu X; Luo J; Shao Z; Shen K
    Cancer Sci; 2010 Oct; 101(10):2220-6. PubMed ID: 20701607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.